Key Insights from the Heart of Pharma: an exclusive CPHI Online report

CPHI Milan, held from October 8–10, 2024 in the historic Fiera Milano, celebrated its 35th edition of bringing together the pharmaceutical industry and supply chain for 3 days of collaborating and innovating. Our first CPHI Wrap-Up Report brings you the latest insight and key takeaways from the Heart of Pharma.
This report dives into 3 days of connecting with pharmaceutical experts, thought leaders, and changemakers. Exclusive interviews with CPHI Milan speakers, deep dives into conference sessions on Manufacturing 5.0, Sustainable Futures, and Next-Gen Bio, emerging pharmaceutical trends from expert roundtables, and observations from the very people who bring CPHI to life are just some of the highlights we bring back from the show floor.
In addition, the CPHI Awards and CPHI Celebration brought two new award categories, the Woman of the Year award and the Future Leader award, to highlight the amazing work of the CPHI team in platforming a diverse body of pharmaceutical professionals.
A keen focus on sustainability and diversity remains a core part of what we do at CPHI, both at our shows and online. This report will bring you unique perspectives on the pharmaceutical industry can put initiatives into action.
At CPHI, we are dedicated to connecting professionals throughout the pharmaceutical supply chain, both at our events and throughout the year with our digital marketing offerings. We are proud to have published four Trend Reports this last year, with two more coming up: the CPHI Middle East Biotech Report and our annual Pharma Trends Outlook for 2025. As we continue to grow and meet the needs of the B2B pharmaceutical sector, we hope that this CPHI Milan Post-Show Report will enable all to understand the biggest trends and conversations happening throughout the pharmaceutical industry today
Download your free Wrap-Up Report here.
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.